GH | Claims Analysis and Forecast | 4Q19 Upside, but More Modest Than 3Q19

12/19/19 04:56PM EST

OVERVIEW

Our proprietary claims data, which we factor into both a Claims Index and Patient Index, indicates upside to 4Q19 in clinical sample volume.  Compared to 3Q19 trends, there is less upside heading into 4Q19 earnings where company guidance calls for 48,000 tests for the year and an implied clinical test volume of 13,345 for the quarter.   Sequentially the trend continues to ramp steadily even before the announcement of Medicare's final LCD covering advanced tumors which was announced a this afternoon.  Going forward it will be useful to see the trend in non lung cancer testing according to the diagnosis code on the submitted claim.

GH | Claims Analysis and Forecast | 4Q19 Upside, but More Modest Than 3Q19 - GH4

GH | Claims Analysis and Forecast | 4Q19 Upside, but More Modest Than 3Q19 - GH3

GH | Claims Analysis and Forecast | 4Q19 Upside, but More Modest Than 3Q19 - GH1

GH | Claims Analysis and Forecast | 4Q19 Upside, but More Modest Than 3Q19 - GH2

Thomas Tobin
Managing Director


Twitter
LinkedIn

Emily Evans
Managing Director – Health Policy



Twitter
LinkedIn

© 2024 Hedgeye Risk Management, LLC. The information contained herein is the property of Hedgeye, which reserves all rights thereto. Redistribution of any part of this information is prohibited without the express written consent of Hedgeye. Hedgeye is not responsible for any errors in or omissions to this information, or for any consequences that may result from the use of this information.